title: Moxifloxacin and gatifloxacin for initial therapy of tuberculosis: a meta-analysis of randomized clinical trials.
abstract: Moxifloxacin (MOX) and gatifloxacin (GAT) have exhibited promising mycobactericidal activity, and a number of clinical trials have been conducted in recent decades to compare the treatment efficacy of MOX-containing and/or GAT-containing regimens with the standard regimen. The aim of this meta-analysis for clinical trials of MOX- or GAT-containing regimens was to evaluate their treatment efficacy and safety in initial therapy for drug-sensitive tuberculosis (TB). Databases were searched for randomized controlled trials, and nine studies with 6980 patients were included. We found that fluoroquinolone substitution for isoniazid or ethambutol in short-course regimens might result in more frequent unfavorable treatment outcomes compared with the standard regimen-in particular, an increased incidence of relapse. In a per-protocol analysis, MOX-containing regimens had slightly higher rates of sputum culture conversion at two months than the standard regimen (RR 1.08, 95% CI 1.04-1.11, P <0.001); there was no significant difference in the rate of sputum conversion between the GAT-containing regimens and the standard regimen (RR 1.13, 95% CI 0.96-1.33, P = 0.13). There were no significant differences in the incidence of death from any cause, including TB, nor were there serious adverse events between the MOX- or GAT-containing regimens and the standard regimen. In conclusion, MOX or GAT might not have the ability to shorten treatment duration in the initial therapy for tuberculosis despite the non-inferiority or even slightly better efficacy in the early phase of treatment compared with the standard regimen. Furthermore, it is safe to include MOX or GAT in initial TB treatment.
authors.forename: Qiaoling
authors.initials: Q
authors.lastname: Ruan
authors.forename: Qihui
authors.initials: Q
authors.lastname: Liu
authors.forename: Feng
authors.initials: F
authors.lastname: Sun
authors.forename: Lingyun
authors.initials: L
authors.lastname: Shao
authors.forename: Jialin
authors.initials: J
authors.lastname: Jin
authors.forename: Shenglei
authors.initials: S
authors.lastname: Yu
authors.forename: Jingwen
authors.initials: J
authors.lastname: Ai
authors.forename: Bingyan
authors.initials: B
authors.lastname: Zhang
authors.forename: Wenhong
authors.initials: W
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000995:Antitubercular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D024841:Fluoroquinolones / Q000009:adverse effects / Q000627:therapeutic use*; D000077734:Gatifloxacin; D006801:Humans; D008297:Male; D000077266:Moxifloxacin; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D014376:Tuberculosis / Q000188:drug therapy* / Q000401:mortality / Q000451:nursing
chemical_list: D000995:Antitubercular Agents; D024841:Fluoroquinolones; D000077734:Gatifloxacin; D000077266:Moxifloxacin